[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 311
Citations 0
News From the Food and Drug Administration
July 5, 2016

New Bladder Cancer Drug

JAMA. 2016;316(1):24. doi:10.1001/jama.2016.8071

The FDA has approved atezolizumab to treat urothelial carcinoma, the most common type of bladder cancer. Marketed as Tecentriq, the drug is the first PD-1/PD-L1 inhibitor, a form of immunotherapy, approved to treat bladder cancer.

Atezolizumab’s safety and efficacy were studied in a single-group trial with 310 patients who had locally advanced or metastatic urothelial carcinoma. About 15% of the patients treated had at least partial shrinkage of their tumors lasting from 2 to 14 months. Among patients who had high levels of PD-L1 protein expression, 26% experienced some tumor shrinkage compared with 9.5% who had low levels of PD-L1 expressed (http://1.usa.gov/206G1Nc).

First Page Preview View Large
First page PDF preview
First page PDF preview
×